GlassScriptPhysician profile
Ronald L Moy
NPI 1467486076
$4,053.40
in general payments reported to CMS, 2019-2025
33 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $314 · 2021: $233 · 2022: $290 · 2023: $616 · 2024: $1,520 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $450.95 | 2022-2024 | Sotyktu |
| Abbvie INC. | $428.64 | 2023-2025 | |
| Organogenesis INC. | $395.91 | 2024-2025 | Cygnus Dual, Puraply Am |
| Strata Skin Sciences, INC. | $393.13 | 2019-2024 | Xtrac |
| Regeneron Healthcare Solutions, INC. | $338.94 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $205.75 | 2019-2025 | Dysport |
| Pfizer INC. | $188.90 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $184.59 | 2019-2025 | Ilumya |
| Allergan, INC. | $145.92 | 2019-2022 | |
| Dermira, INC. | $125.00 | 2019 | |
| Merz North America, INC. | $119.74 | 2019-2024 | Xeomin |
| Smith+Nephew, INC. | $113.68 | 2022-2025 | Grafix Pl, Oasis Micro, Grafix Xc |
| Janssen Biotech, INC. | $108.08 | 2022-2023 | Simponi, Simponi Aria, Remicade |
| Mimedx Group, INC. | $103.14 | 2024-2025 | |
| Leo Pharma INC. | $96.73 | 2021-2024 | Adbry |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $91.59 | 2019 | |
| Revance Therapeutics, INC. | $78.20 | 2024 | Daxxify |
| Ucb, INC. | $69.12 | 2024-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $61.97 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.76 | 2020-2024 | Jublia, Cabtreo, Arazlo |
| Lilly USA, LLC | $30.80 | 2025 | Taltz, Zepbound, Ebglyss |
| Polarityte, INC. | $30.33 | 2020 | |
| Amgen INC. | $27.27 | 2020 | |
| Krystal Biotech INC | $26.11 | 2023 | Vyjuvek |
| Bioventus LLC | $25.93 | 2022 | |
| Stimlabs LLC | $23.99 | 2025 | Corplex P |
| Almirall LLC | $23.26 | 2025 | Seysara |
| Solta Medical, A Division of Bausch Health US, LLC | $22.95 | 2024 | Clear & Brilliant |
| Incyte Corporation | $22.89 | 2022 | |
| Mayne Pharma Commercial LLC | $19.59 | 2019 | |
| Misonix INC | $16.03 | 2021 | |
| Aclaris Therapeutics, INC. | $15.81 | 2019 | |
| Merck Sharp & Dohme LLC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.